{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Lemieux C"],"funding":["NIH HHS"],"pagination":["85"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12939802"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["33(2)"],"pubmed_abstract":["CD19 CAR T-cell therapy has significantly improved the survival of patients with relapsed or refractory large B cell lymphoma (R/R LBCL) and is considered standard of care for eligible patients in Canada. Axicabtagene ciloleucel (axi-cel) is an autologous CAR T-cell therapy, initially approved by Health Canada for adults with R/R LBCL after 2 or more lines of therapy. This multi-centre analysis, with registry data collected from CIBMTR, aims to present a Canadian perspective on the real-world experience of axi-cel in patients with R/R LBCL. With a median follow-up of 12.4 months, the best objective response rate (ORR) and complete response (CR) rate among all patients were 77% and 59%, respectively. At 12 months, estimated progression-free survival (PFS) and overall survival (OS) were 49% "],"journal":["Current oncology (Toronto, Ont.)"],"pubmed_title":["Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada."],"pmcid":["PMC12939802"],"funding_grant_id":["1U24CA076518-28","1U24CA233032-23"],"pubmed_authors":["Wang HL","Nissen F","Kim JJ","Feng Z","Li SZL","Shafey M","Pasquini MC","Lee G","Hu ZH","Kuruvilla J","Logan B","Hay K","Paulson K","Billen L","Lemieux C","Davison K"],"additional_accession":[]},"is_claimable":false,"name":"Real-World Outcomes of Axicabtagene Ciloleucel for Treatment of Relapsed or Refractory Large B-Cell Lymphoma in Canada.","description":"CD19 CAR T-cell therapy has significantly improved the survival of patients with relapsed or refractory large B cell lymphoma (R/R LBCL) and is considered standard of care for eligible patients in Canada. Axicabtagene ciloleucel (axi-cel) is an autologous CAR T-cell therapy, initially approved by Health Canada for adults with R/R LBCL after 2 or more lines of therapy. This multi-centre analysis, with registry data collected from CIBMTR, aims to present a Canadian perspective on the real-world experience of axi-cel in patients with R/R LBCL. With a median follow-up of 12.4 months, the best objective response rate (ORR) and complete response (CR) rate among all patients were 77% and 59%, respectively. At 12 months, estimated progression-free survival (PFS) and overall survival (OS) were 49% ","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-11T03:13:50.752Z","creation":"2026-07-11T03:11:25.435Z"},"accession":"S-EPMC12939802","cross_references":{"pubmed":["41744849"],"doi":["10.3390/curroncol33020085"]}}